Analysis of diagnostic value of lncRNA HCP5 in immune thrombocytopenia and its predictive value for disease progression.

IF 2.1 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-10-10 DOI:10.1080/17474086.2025.2570330

Yunqi Liu, Dingqiong Wang, Hong Zhang, Jinfeng Du, Yi Liao

{"title":"Analysis of diagnostic value of lncRNA HCP5 in immune thrombocytopenia and its predictive value for disease progression.","authors":"Yunqi Liu, Dingqiong Wang, Hong Zhang, Jinfeng Du, Yi Liao","doi":"10.1080/17474086.2025.2570330","DOIUrl":null,"url":null,"abstract":"Background: Studies showed that lncRNA HCP5 was associated with a variety of autoimmune diseases. This study evaluated the diagnostic potential of lncRNA HCP5 for immune thrombocytopenia (ITP) and its prognostic value in predicting disease progression, offering clinical application insights.Research design and methods: This study analyzed 40 ITP patients and 40 controls. qRT-PCR measured lncRNA HCP5 expression, while flow cytometry quantified Th17/Treg percentages. Pearson correlation assessed HCP5-clinical feature relationships. ROC analysis determined diagnostic potential, and Kaplan-Meier/Cox regression evaluated prognostic significance.Results: ITP patients showed decreased platelet counts, Treg percentages, and lncRNA HCP5 levels, but increased Th17%s versus controls. LncRNA HCP5 showed positive correlation with platelets/Tregs but negative with Th17 cells, and was associated with ITP bleeding severity. With a cutoff of 0.825, lncRNA HCP5 had an AUC of 0.979 for ITP diagnosis, sensitivity of 0.900, and specificity of 0.925. Kaplan-Meier analysis showed increased 1-year recurrence with low HCP5 expression, and Cox regression confirmed it as a poor prognostic factor.Conclusions: LncRNA HCP5 expression correlated significantly with Treg cell percentage, Th17 cell percentage, and the degree of bleeding in ITP patients. LncRNA HCP5 has high diagnostic and prognostic value for ITP.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2570330","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Studies showed that lncRNA HCP5 was associated with a variety of autoimmune diseases. This study evaluated the diagnostic potential of lncRNA HCP5 for immune thrombocytopenia (ITP) and its prognostic value in predicting disease progression, offering clinical application insights.

Research design and methods: This study analyzed 40 ITP patients and 40 controls. qRT-PCR measured lncRNA HCP5 expression, while flow cytometry quantified Th17/Treg percentages. Pearson correlation assessed HCP5-clinical feature relationships. ROC analysis determined diagnostic potential, and Kaplan-Meier/Cox regression evaluated prognostic significance.

Results: ITP patients showed decreased platelet counts, Treg percentages, and lncRNA HCP5 levels, but increased Th17%s versus controls. LncRNA HCP5 showed positive correlation with platelets/Tregs but negative with Th17 cells, and was associated with ITP bleeding severity. With a cutoff of 0.825, lncRNA HCP5 had an AUC of 0.979 for ITP diagnosis, sensitivity of 0.900, and specificity of 0.925. Kaplan-Meier analysis showed increased 1-year recurrence with low HCP5 expression, and Cox regression confirmed it as a poor prognostic factor.

Conclusions: LncRNA HCP5 expression correlated significantly with Treg cell percentage, Th17 cell percentage, and the degree of bleeding in ITP patients. LncRNA HCP5 has high diagnostic and prognostic value for ITP.

查看原文本刊更多论文

lncRNA HCP5在免疫性血小板减少症中的诊断价值及其对疾病进展的预测价值分析。

背景：研究表明lncRNA HCP5与多种自身免疫性疾病相关。本研究评估了lncRNA HCP5对免疫性血小板减少症（ITP）的诊断潜力及其在预测疾病进展方面的预后价值，为临床应用提供见解。研究设计与方法：本研究分析了40例ITP患者和40例对照组。qRT-PCR检测lncRNA HCP5表达，流式细胞术检测Th17/Treg百分比。Pearson相关性评估hcp5与临床特征的关系。ROC分析确定诊断潜力，Kaplan-Meier/Cox回归评估预后意义。结果：ITP患者血小板计数、Treg百分比和lncRNA HCP5水平下降，但与对照组相比增加了th17%。LncRNA HCP5与血小板/ treg呈正相关，与Th17细胞呈负相关，且与ITP出血严重程度相关。lncRNA HCP5诊断ITP的AUC为0.979，灵敏度为0.900，特异性为0.925，截止值为0.825。Kaplan-Meier分析显示HCP5低表达的1年复发率增加，Cox回归证实其为不良预后因素。结论：LncRNA HCP5表达与ITP患者Treg细胞百分比、Th17细胞百分比及出血程度相关。LncRNA HCP5对ITP有较高的诊断和预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.